PMID- 28681218
OWN - NLM
STAT- MEDLINE
DCOM- 20180416
LR  - 20181113
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 34
IP  - 8
DP  - 2017 Aug
TI  - Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for 
      locally advanced cervical cancer: a prospective multicenter phase II trial with a 
      dose-finding study.
PG  - 134
LID - 10.1007/s12032-017-0992-4 [doi]
AB  - The aim of this study is to evaluate the outcome and safety of the 
      multidisciplinary strategy using cisplatin plus dose-dense paclitaxel (dose-dense 
      TP) before and after radical hysterectomy (RH) for stage IB2, IIA2, or IIB 
      patients with cervical cancer. In the dose-finding phase, 12 patients received 3 
      cycles of cisplatin (75 mg/m(2), day 1) with paclitaxel (70 or 80 mg/m(2), days 
      1, 8, and 15) every 21 days as neoadjuvant chemotherapy (NAC). In the phase II 
      study, 51 patients received 3 cycles of dose-dense TP at the recommended dose as 
      NAC, and another 2 cycles of the same regimen after RH. The primary endpoint was 
      2-year progression-free survival (PFS). The secondary endpoints were 2-year 
      overall survival (OS), adverse events (AEs), response rate (RR), and pathological 
      complete response (pCR) rates. The recommended dose of paclitaxel at dose-finding 
      phase was 80 mg/m(2). In the phase II study, 34 patients (66.7%) had FIGO stage 
      IIB disease. The RR and pCR rates were 94 and 28%. With a median follow-up 
      duration of 58 months, each of the 2- and 5-year PFS rates was 88.2%, the 2- and 
      5-year OS rates were 94.1 and 88.2%, respectively. The incidence of grade 3/4 AEs 
      was neutropenia (34%), nausea (12%), appetite loss (10%), fatigue (6%), and 
      anemia (6%). Febrile neutropenia was uncommon (2%). Dose-dense TP before and 
      after RH achieved a good long-term survival and was feasible for patients with 
      locally advanced cervical cancer.
FAU - Tanioka, Maki
AU  - Tanioka M
AUID- ORCID: 0000-0002-6558-2246
AD  - Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi, 
      Hyogo, 673-8558, Japan. makitanioka123456@yahoo.co.jp.
FAU - Yamaguchi, Satoshi
AU  - Yamaguchi S
AD  - Gynecologic Oncology, Hyogo Cancer Center, Akashi, Japan.
FAU - Shimada, Muneaki
AU  - Shimada M
AD  - Gynecologic Oncology Division, Tohoku University Hospital, Sendai, Japan.
FAU - Nagao, Shoji
AU  - Nagao S
AD  - Gynecologic Oncology, Saitama University International Medical Center, Hidaka, 
      Japan.
FAU - Takehara, Kazuhiro
AU  - Takehara K
AD  - Obstetrics and Gynecology, Kure Medical Center/Chugoku Cancer Center, Kure, 
      Japan.
FAU - Nishimura, Masato
AU  - Nishimura M
AD  - Obstetrics and Gynecology, School of Medicine University of Tokushima, Tokushima, 
      Japan.
FAU - Morita, Satoshi
AU  - Morita S
AD  - Biomedical Statistics and Bioinformatics, Kyoto University, Kyoto, Japan.
FAU - Negoro, Shunichi
AU  - Negoro S
AD  - Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi, 
      Hyogo, 673-8558, Japan.
FAU - Fujiwara, Kiyoshi
AU  - Fujiwara K
AD  - Gynecologic Oncology, Hyogo Cancer Center, Akashi, Japan.
FAU - Kigawa, Junzo
AU  - Kigawa J
AD  - Gynecologic Oncology Division, Tottori University Hospital, Yonago, Japan.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
DEP - 20170705
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Cisplatin/administration & dosage
MH  - Disease-Free Survival
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Hysterectomy
MH  - Middle Aged
MH  - Nausea/chemically induced
MH  - Neutropenia/chemically induced
MH  - Paclitaxel/administration & dosage
MH  - Treatment Outcome
MH  - Uterine Cervical Neoplasms/*drug therapy/pathology/*surgery
OTO - NOTNLM
OT  - Cervical cancer
OT  - Cisplatin
OT  - Dose dense
OT  - Paclitaxel
OT  - Pathological complete response
OT  - Phase II
EDAT- 2017/07/07 06:00
MHDA- 2018/04/17 06:00
CRDT- 2017/07/07 06:00
PHST- 2017/04/22 00:00 [received]
PHST- 2017/06/30 00:00 [accepted]
PHST- 2017/07/07 06:00 [entrez]
PHST- 2017/07/07 06:00 [pubmed]
PHST- 2018/04/17 06:00 [medline]
AID - 10.1007/s12032-017-0992-4 [pii]
AID - 10.1007/s12032-017-0992-4 [doi]
PST - ppublish
SO  - Med Oncol. 2017 Aug;34(8):134. doi: 10.1007/s12032-017-0992-4. Epub 2017 Jul 5.